Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease

NeuroReport

Volumn 17, Issue 11, 2006, Pages 1215-1218

  Sasaki, Makoto ^a   Shibata, Eri ^a   Tohyama, Koujiro ^a   Takahashi, Junko ^a   Otsuka, Kotaro ^a   Tsuchiya, Kuniaki ^b   Takahashi, Satoshi ^a   Ehara, Shigeru ^a   Terayama, Yasuo ^a   Sakai, Akio ^a  

^a IWATE MEDICAL UNIVERSITY   (Japan)

^b TOKYO METROPOLITAN MATSUZAWA HOSPITAL   (Japan)

Author keywords

Locus ceruleus; Magnetic resonance imaging; Neuromelanin; Parkinson's disease; Substantia nigra

Indexed keywords

NEUROMELANIN;

ADULT; AGED; ARTICLE; BRAIN STEM; CLINICAL ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; FEMALE; HUMAN; HUMAN TISSUE; LOCUS CERULEUS; MALE; NORADRENERGIC NERVE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PRIORITY JOURNAL; SCINTISCANNING; SUBSTANTIA NIGRA;

AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LOCUS COERULEUS; MAGNETIC RESONANCE IMAGING; MALE; MELANINS; MIDDLE AGED; PARKINSON DISEASE; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; SUBSTANTIA NIGRA;

EID: 33745896818     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.wnr.0000227984.84927.a7     Document Type: Article

References (18)

1. Greenfield JG, Bosanquet FD. The brain stem lesions in Parkinsonism. J Neurol Neurosurg Psychiatr 1953; 16:213-225.
2. Mann DMA, Yates PO. Pathological basis for neurotransmitter changes in Parkinson's disease. Neuropathol Appl Neurobiol 1983; 9:3-19.
3. Adachi M, Hosoya T, Haku T, Yamaguchi K, Kawanami T. Evaluation of the substantia nigra in patients with Parkinsonian syndrome accomplished using multishot diffusion weighted MR imaging. Am J Neuroradiol 1999; 20:1500-1506.
4. Oikawa H, Sasaki M, Tamakawa Y, Ehara S, Tohyama K. The substantia nigra in Parkinson disease: proton density-weighted spin-echo and fast short inversion time inversion-recovery MR findings. Am J Neuroradiol 2002; 23:1747-1756.
5. Bazelon M, Fenichel GM, Randall J. Studies on neuromelanin: I. a melanin system in the human adult brainstem. Neurology 1967; 17:512-518.
6. Drayer B, Burger P, Darwin R, Riederer S, Herfkens R, Johnson GA. MRI of brain iron. Am J Roentgenol 1986; 147:103-110.
7. Huber SJ, Chakeres DW, Paulson GW, Khanna R. Magnetic resonance imaging in Parkinson's disease. Arch Neurol 1990; 47:735-737.
8. Marsden D. Brain pigment and its relation to brain catecholamines. Lancet 1965; 10:475-476.
9. Graham DG. On the origin and significance of neuromelanin. Arch Pathol Lab Med 1979; 103:359-362.
10. Enochs WS, Nilges MJ, Swartz HM. Purified human neuromelanin, synthetic dopamine melanin as a potential model pigment, and the normal human substantia nigra: characterization by electron paramagnetic resonance spectroscopy. J Neurochem 1993; 61:68-79.
11. Enochs WS, Hyslop WB, Bennett HF, Brown RD, Koenig SH, Swartz HM. Sources of the increased longitudinal relaxation rates observed in melanotic melanoma: an in vitro study of synthetic melanins. Invest Radiol 1997; 24:794-804.
12. Enochs WS, Petherick P, Bogdanova A, Mohr U, Weissleder R. Paramagnetic metal scavenging by melanin: MR imaging. Radiology 1997; 204:417-423.
13. Ugurbil K, Garwood M, Ellermann J. Imaging at high magnetic fields: initial experiences at 3 T. Magn Reson Q 1993; 9:259-277.
14. Wansapura JP, Holland SK, Dunn RS, Ball WS. NMR relaxation times in the human brain at 3.0 Tesla. J Magn Reson Imaging 1999; 9:531-538.
15. Melki PS, Mulkern RV. Magnetization transfer effects in multislice RARE sequences. Magn Reson Med 1992; 24:189-195.
16. Mann DM, Yates PO. Possible role of neuromelanin in the pathogenesis of Parkinson disease. Mech Ageing Dev 1983; 21:193-203.
17. Hallgren B, Sourander P. The effect of age of the non/hemin iron in the human brain. J Neurochem 1958; 3:41-51.
18. Vymazal J, Righini A, Brooks RA, Canesi M, Mariani C, Leonardi M, et al. T1 and T2 in the brain of healthy subjects, patients with Parkinson disease, and patients with multiple system atrophy: relation of iron content. Radiology 1999; 211:489-495.